TickerTalks
Browse all tickers →
TickerTalks›$DARE
DADARE

Dare Bioscience, Inc.

Rising onWhy it's trendingX chatter picking upStrong bullish X conversationBacked by solid revenue growth
$DARE·$19M·Biotechnology·Healthcare
$1.94-0.5%YTD+0.5%1Y-26.0%
Mentions · last 7 days
2026-07-09: 7 posts2026-07-10: 5 posts2026-07-11: 9 posts2026-07-12: 9 posts2026-07-13: 15 posts2026-07-14: 8 posts2026-07-15: 12 posts65+8%
Price updated 7m ago·X counts updated 2d ago
DADARE
$DAREDare Bioscience, Inc.
$1.94-0.52%65 posts+8%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Today's AI verdict on what's driving $DARE, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventWinding up for a moveAI verdict · as of 2026-07-17

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

DARE Bioscience is launching Flora Sync in June 2026 — the X chatter is a mix of the biotech thesis and a Solana memecoin.

DARE Bioscience is a specific women's-health biotech launching Flora Sync LF5 vaginal probiotic capsules — the specific first consumer-health product designed to restore microbiome balance.

Where the setup reads:

  • The Flora Sync launch is category-defining: the specific first consumer-health product from DARE is the specific commercial-catalyst that anchors the multi-quarter thesis.
  • The economics are pre-scale: 6% gross margin at -10% operating margin means DARE is in a specific unit-economics gap that requires the Flora Sync commercial ramp to arrive.
  • The tape is compressed: sitting 8.3% below the 50-day but 4% above the 200-day at 10% of the 52-week range — a compressed base with specific commercial-catalyst approaching.
  • The X chatter is a mix: the biotech investor-thread on the probiotic launch is the specific equity-relevant signal, while the Solana memecoin $DARE thread is a ticker collision to filter out.

Aug 13 earnings is the trigger. A number confirming specific Flora Sync launch progress plus commercial-partnership commentary extends the leg materially; a soft launch print with muted commercial commentary is the specific setup for the coil to break lower.

Agrees with X sentimentX is bullish on the biotech thesis — the Flora Sync launch is a specific commercial catalyst. The corpus is honest that the Solana memecoin $DARE is a separate ticker-collision narrative — filter to the biotech-focused signal.

What to watch: The Aug 13 print — Flora Sync launch progress, commercial-partnership commentary, and cash-runway update. Above-consensus launch progress extends the leg; a soft print activates the coil-break risk.

On the calendar: 2026-08-13 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment27 posts analyzed · as of 2026-06-11

DARE Bioscience announced the upcoming launch of Flora Sync LF5 vaginal probiotic capsules in June 2026, marking the company's first consumer health product designed to restore microbiome balance. Separately, a Solana memecoin $DARE deployed by the DareBounties team is gaining traction with viral video challenges paying out in $DARE for completing dares. The token hit $270K market cap and is gaining momentum with 7.8x calls landing. The conversation splits between biotech investors discussing the probiotic launch and Solana-degens shilling the dare-token. Sentiment skews bullish in both narratives with the meme-coin dominant for short-term momentum and conviction-buyer biotech thesis for long-term.

Read the AI verdict + X sentiment for $DARE

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biopharma developing contraception, fertility, and vaginal health products for women, with one FDA-approved drug (XACIATO).

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $DARE.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $DARE

Neutral — Clinical-stage biopharma developing contraception, fertility, and vaginal health products for women, with one FDA-approved drug (XACIATO); end markets and revenue mix have limited overlap with the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.7%YTD
+44.5%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.3How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-151%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-10.3%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-56.8%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
15.5Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
7.6%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
5.6%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
9.8Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 14, 2026$-0.20$-0.33+39.4%
Q4 2025Mar 26, 2026$-0.02$-0.24+91.7%
Q3 2025Nov 13, 2025$-0.28$-0.33+15.2%
Q2 2025Aug 14, 2025$-0.45$-0.55+18.2%
Next earningsThu, Aug 13·consensus EPS $-0.33

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$152K+499.6%-423%-1967%$-0.21$-5.5M
Q4 FY25$1.0M-1708.4%71.1%-144%$-0.10$1.2M
Q3 FY25$2K-94.6%100%-162341%$-0.28$-617K
Q2 FY25$-21K-194.4%100%18080%$-0.45$-5.3M

Forward consensus

5-year forecast · up to 2 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$2.1M$1.8M – $2.6M-$0.95-$1.34 – -$0.562
FY27$7.4M$6.2M – $9.1M-$0.48-$0.62 – -$0.381
FY28$34.7M$29.0M – $42.6M$0.02$0.02 – $0.032
FY29$101.9M$85.4M – $125.2M$1.41$1.11 – $1.821
FY30$235.8M$197.6M – $289.6M$4.93$3.89 – $6.401

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.4×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.10%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-8.3%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.+4.1%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatTiny float · 9.4M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today0.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β1.025-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 13 other (13 awards) in window

See when $DARE insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KPress release / Reg FDJul 138-K — Item 7.01: Press release / Reg FD
AI summary

Daré Bioscience (DARE) — 8-K (Item 7.01) furnishing a corporate presentation as of July 13, 2026, to be used in meetings with investors and analysts per Regulation FD. The presentation covers Daré's pipeline and corporate strategy. Administrative — investor presentation filed for Reg FD compliance; no new material disclosures beyond pipeline information in the deck.

8-KPress release / Reg FDJun 228-K — Item 7.01: Press release / Reg FD
AI summary

Dare Bioscience, Inc. filed an 8-K under Reg FD on June 22, 2026 disclosing that it is using a corporate investor presentation (dated June 22, 2026, Exhibit 99.1) in meetings with securities market participants commencing that day. The presentation will be available on the company's IR website under Presentations. The content of the presentation is not included in the 8-K body. Routine Reg FD compliance filing for investor outreach — informational only, with no disclosed material corporate event.

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change · Item 5.07: Shareholder vote
AI summary

Daré Bioscience, Inc. held its 2026 Annual Meeting on June 11, 2026. Shareholders elected Class III directors Gregory W. Matz (3.75M for) and Sabrina Martucci Johnson (3.85M for); ratified Haskell & White LLP as auditor; approved amendments to the 2022 Stock Incentive Plan adding 1,500,000 shares; and voted on additional proposals per the April 28, 2026 proxy. The equity plan addition of 1.5M shares is mildly dilutive for this small-cap women's health biotech.

8-KUnregistered equity saleMay 188-K — Item 3.02: Unregistered equity sale
AI summary

Daré Bioscience, Inc. (DARE) completed closings of its Regulation A offering on May 14, 2026, issuing 50,000 Investor Units — each consisting of one share of Series A Convertible Preferred Stock and two warrants to purchase common stock — at $5.00 per unit, for $250,000 aggregate proceeds. The warrants allow purchase of up to 100,000 additional common shares. This is part of a larger Regulation A program of up to 4,854,000 units (Form 1-A offering statement). This is a small-scale, dilutive equity/warrant capital raise for a clinical-stage women's health biotech.

8-KUnregistered equity saleMay 78-K — Item 3.02: Unregistered equity sale
AI summary

DARE filed an 8-K (Item 3.02) dated 2026-05-07. (“Daré” “we,” “us,” or “our”) completed closings of its previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively the “Investor Units”), each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and two warrants, each to purchase one share of our common.

8-KPress release / Reg FDApr 228-K — Item 7.01: Press release / Reg FD
AI summary

DARE filed an 8-K Item 7.01 (Reg FD) disclosure dated 2026-04-22. Covers: presentation in the “Investors” section of its website (https://ir. Reg FD disclosures make material information simultaneously available to all investors; content may include guidance updates, strategic plans, or preliminary results.

8-KUnregistered equity saleApr 208-K — Item 3.02: Unregistered equity sale
AI summary

DARE filed an 8-K (Item 3.02) dated 2026-04-20. (“Daré” “we,” “us,” or “our”) completed a closing of our previously announced Regulation A offering of up to 4,854,000 units (each, an “Investor Unit” and collectively the “Investor Units”), each consisting of one share of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) and two warrants, each to purchase one share of our commo.

8-KOfficer or director changeApr 178-K — Item 5.02: Officer or director change
AI summary

DARE disclosed a personnel change (8-K Item 5.02, dated 2026-04-17). An executive departure and a new appointment are both reported. Personnel changes are generally administrative; materiality depends on seniority and circumstances.

+ 20 other (5 8-Ks · 4 proxys · 2 253G2s · 2 earnings 8-Ks) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Eventglobenewswire.com·8d agoDaré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Eventglobenewswire.com·8d agoDaré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platformglobenewswire.com·16d agoDaré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segmentglobenewswire.com·22d agoDaré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026globenewswire.com·29d ago

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$SLS$AURA$ATAI
Voices on X · last 7 days

No standout posts about $DARE on X in the last 7 days.

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport